Ocular neovascularization (NV) is the critical pathologic process and the leading cause of blindness in a variety of eye diseases such as retinopathy of prematurity (ROP); diabetic retinopathy (DR); and AMD.1 These diseases can be divided into vitreal vascular diseases, in which there is leakage and/or NV from retinal vessels, and subretinal or choroidal NV, in which new vessels grow into the normally avascular outer retina and subretinal space.2 These fragile new vessels can easily hemorrhage and cause irreversible vision loss. It has been well elucidated that VEGF plays an important role in this pathologic process.2 Although treatments involving VEGF antagonists have provided major benefits for patients with ROP and neovascular AMD,3,4 frequent injections are required to sustain efficacy and treatment resistance frequently occurs. In addition, the procedure poses a heavy economic burden on patients due to multiple injections. In 2012, aflibercept, a fusion protein that blocks VEGFA, VEGFB, and placental growth factor (PIGF), was approved for the treatment of macular degeneration.5 Intravitreal injection of aflibercept achieved an equivalent effect in improving the best-corrected visual acuity (BCVA) and preventing BCVA loss in AMD while requiring fewer injections when compared to ranibizumab monotherapy,6 thus indicating the need to develop additional antagonists to other ocular NV targets that could be used as potential combination therapy.

One way to address this unmet need is to target other relevant angiogenic biomarkers like endocan. In our previous study, our microarray analysis suggested that endocan was one of the most significantly upregulated genes with a more than 15-fold increase in mRNA expression levels in the OIR model compared to control. Endocan (also known as endothelial cell specific molecule-1), a soluble dermatan sulfate proteoglycan, has been found to be expressed in endothelial tip cells in several retinal angiogenesis models.7 For example, animal experiments demonstrated that following hypoxic exposure, the expression of endocan in immature retinas, especially in endothelial tip cells of 1-day old Wistar rats, was increased from 3 hours to 14 days.7 Clinical research demonstrated that endocan levels were significantly higher in the vitreous fluid from patients with proliferative DR (PDR) compared to nondiabetic control patients. Furthermore, the expression level of endocan in active PDR patients was also higher than that in inactive PDR.8 Endocan is also strongly overexpressed in various carcinomas such as renal cancer, non-small lung cancer, hepatocarcinoma, glioblastoma, and bladder cancer. High
endocan expressions can be identified as part of the molecular signatures defining a poor prognosis and prediction of recurrence in some malignant tumors. Interestingly, in mice models of tumor xenografts, overexpression of human endocan induced tumor growth of non-tumorigenic human embryonic kidney cells and accelerated tumor growth of the tumorigenic cells. Blockade of endocan with a monoclonal antibody in these models resulted in a notable reduction of tumor growth. In addition, multiple studies have demonstrated that endocan silencing decreased tumor cells survival, migration, and invasion. By using endocan knockout mice, Rocha et al. reported that endocan was required for an optimal response to VEGF stimulation and played a role in retinal angiogenesis. In vitro, in the absence of endocan, human umbilical vein endothelial cells disturbed VEGF-induced or fibroblast growth factor 2-induced sprouting angiogenesis. Given the existing literature regarding endocan, we hypothesized that endocan may be involved in the regulation of ocular NV. The aim of this study was to investigate the role of endocan in ocular NV regulation and its potential interactions with VEGF in several experimental NV mouse models and cell assays.

**MATERIALS AND METHODS**

**Cell Culture**

In in vitro studies, HRECs were cultured with endothelial cell medium (ECM) containing 5% fetal bovine serum (FBS) and 100 U/mL penicillin-streptomycin at 37°C under a humidified 95%: 5% (vol/vol) mixture of air and CO2. Before the tube formation assay, 100 μL of chilled membrane matrix (Matrigel; Corning Life Sciences, Tewksbury, MA, USA) was added into 96-well culture plates on ice and incubated for 30 minutes at 37°C, followed by preparing HRECs suspensions in complete ECM. Approximately 2.5 × 10⁴ cells in 200 μL medium with or without rhEndocan were plated onto a layer of the matrix (Corning Life Sciences) in each well. Cell tube formation images were recorded 6 hours later under an inverted microscope (×100), and the number of tubes was counted as described previously. In other experiments, cells were seeded in triplicate in 60 × 15 mm petri dishes. Until cell attachment, the medium was replaced with fresh ECM containing 50 ng/mL and 100 ng/mL of rhEndocan or recombinant human VEGFA (rhVEGFA; Cell Signaling Technology, MA, USA) for the following investigation. Cell lysates were collected and prepared for total RNA and protein isolation.

**Animals**

We used C57BL/6 mice for the purpose of this study and in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research and the guidelines of the Animal Care and Use Committee at Shanghai Jiaotong University Medical School. Mice were housed in a specific pathogen-free environment and rho/VEGF transgenic mice were provided by Professor Peter A. Campochiaro of Johns Hopkins University Medical School. Mice were euthanized at any time point to section the entire retina using the photomerge option of a raster graphics editor (Photoshop CS 6.0; Adobe Systems, San Jose, CA, USA). Imaging software (Image Pro Plus; Media Cybernetics, Inc., Rockville, MD, USA) was used to measure the area of retinal NV per retina by a blinded investigator.

**Mouse Model of Rho/VEGF Transgenic Mice and Flat-Mounts Analysis**

Rho/VEGF transgenic mice, in which the rhodopsin promoter drives the expression of VEGF in photoreceptors so that new vessels sprout from the deep capillary bed of the retina, received an intraocular injection of 0.1 µg mouse endocan NAb in one eye and PBS in the contralateral eye on day 0 and day 7 after rupture of Bruch’s membrane. Mice were euthanized on day 14 to perform immunostaining and flat-mount analysis.

**Immunofluorescence Staining of Endocan and Isolectin**

Mice with OIR and CNV or age-matched controls were euthanized. Their eyes were enucleated and rapidly frozen in embedding medium (Sakura Finetek, Torrance, CA, USA) prior to sectioning. Sections (10 µm) were thawed, air-dried and fixed in 4% paraformaldehyde at room temperature for 10 minutes. These sections were incubated with blocking buffer (PBS containing 10% FBS) for 1 hour, and were then subsequently with goat anti-mouse endothelial antibody (R&D Systems) for 2 hours. They were then incubated with AlexaFluor 555 donkey anti-goat secondary antibody (1:500; Invitrogen, Carlsbad, CA, USA) and isolectin for 1 hour at room temperature in the dark. The nuclei were stained with DAPI (Beyotime Biotechnology, Minneapolis, MN, USA) at a concentration of either 0.01, 0.1, 0.5, or 1 µg/µL; the contralateral eye was treated with PBS. At P17, mice were euthanized and eyes were prepared for immunofluorescent flat-mounts with FITC-labeled isolectin B4 (1:50; Vector Laboratories, Inc., Burlingame, CA, USA) for 1 hour. Retinal sections were washed three times in PBS and flat-mounted with fluorescence mounting medium (DAKO, Agilent Technologies, CA, USA) and sealed with a cover slip. Digital photographs were obtained with a fluorescence microscope (Carl Zeiss Microscopy, Thornwood, NY, USA) at ×5 magnification, and images were merged into a single image to show the entire retina using the photomerge option of a raster graphics editor (Photoshop CS 6.0; Adobe Systems, San Jose, CA, USA). Imaging software (Image Pro Plus; Media Cybernetics, Inc., Rockville, MD, USA) was used to measure the area of retinal NV per retina by a blinded investigator.
mounted with fluorescence mounting medium, and examined and captured with a fluorescence microscope.

**Quantitative Real-Time PCR**

Total RNA in eye tissues and cells was extracted using a commercial reagent (TRIzol; Thermo Fisher Scientific, Wal-tham, MA, USA) following the manufacturer’s guidelines. Total RNA was quantified by spectrophotometer (Thermo NanoDrop 8000; Thermo Fisher Scientific); 1 μg total RNA of each sample was reversely transcribed into complimentary DNA (cDNA) using M-MLV reverse transcriptase system according to the manufacture’s protocol. RT-PCR detection was performed in a 10 μL volume with SYBR Green Mix on an RT-PCR instrument (Light-Cycler 480; Roche Applied Science, Mannheim, Germany). Relative gene expression levels were normalized to cyclophilin A and calculated using the 2–\(\Delta\Delta C_t\) method. Primer sequences could be obtained as follows: Endocan(mouse), 5′-GGAGGATGATTTTGGTGACG-3′ (sense), 5′-CTGTCACA TATGCCGACTG-3′ (antisense); Endocan(human), 5′-CTTCGGGATGGATTGCAGAG-3′ (sense), 5′-CAGATGCCATGT CATGCTCC-3′ (antisense); MMP-2(mouse), 5′-GCTCTGTCCTCCTCTGTAGTTA-3′ (sense), 5′-GGTCACAGTCACCTTTCTT-3′ (antisense); MMP-9(mouse), 5′-TGCACTGGGCTTAGATCATTC-3′ (sense), 5′-TGCCGTCTATGTCGTCTTTATTC-3′ (antisense); PIGF (mouse), 5′-CTTCTGTGACCACTGTCAATCT-3′ (sense), 5′-TCAAAGCTCGCGTTACCTTAT-3′ (antisense); INOS(mouse), 5′-CCGGCATGAAGTACCTGATAT-3′ (sense), 5′-GGTGACAGGTTTCCTCCTATG-3′ (antisense); VEGFA(human), 5′-CTTCAAGCCATCCTGTGTGC-3′ (sense), 5′-CGCTCCAG GACTTAACTCC-3′ (antisense); VEGFR1(mouse), 5′-GAGTC TAAAAATCTTGACCCACATTG-3′ (sense), 5′-CAGTATCA CAATCACCATCAGAG-3′ (antisense); VEGFR2(mouse), 5′-CACCTGCCAGGCCTGCAA-3′ (antisense), 5′-GCTTGGTGACAGGCGCTCTA-3′ (antisense).

**Western Blot**

Fresh isolated eye tissues and cells were lysed, quantified, blotted and developed as previously described. The following primary antibodies were used for the purpose of this experiment: goat anti-mouse endocan antibody (0.1 μg/mL; R&D Systems); rabbit anti-matrix metalloproteinase (MMP)-2 antibody (1:1000; Cell Signaling Technology); MMP-9 antibody (1:1000; Cell Signaling Technology); rabbit anti-PIGF antibody (1:1000; Abcam, Cambridge, UK); goat anti-VEGF antibody (1:1000; Abcam); rabbit anti-VEGFR1 antibody (1:1000; Abcam); rabbit anti-VEGFR2 antibody (Cell Signaling Technology); rabbit anti-P38 antibody (1:1000; Cell Signaling Technology); rabbit anti-phospho (p)-P38 antibody (1:1000; Cell Signaling Technology); rabbit anti-extracellular signal-regulated kinase (ERK) antibody (1:1000; Cell Signaling Technology); rabbit anti–phospho (p)-ERK antibody (1:1000; Cell Signaling Technology); rabbit anti–c-Jun N-terminal kinases (JNK) antibody (1:1000; Cell Signaling Technology) and rabbit anti–p-JNK antibody (1:1000; Cell Signaling Technology).

---

**FIGURE 1.** Endocan expression levels increased in eyes of OIR, CNV, and rho/VEGF transgenic mice models. (A) RT-PCR analysis for endocan mRNA in the retinas of OIR mice at P15 (n = 8) and P18 (n = 8). (B, C) Representative RT-PCR assay results of endocan mRNA expression in retinas from rho/VEGF transgenic (n = 8) at P15 and retina/choroidal complex from CNV mice (n = 8) at day 3 after photocoagulation, respectively. (D) Western blot demonstrates protein expression levels of endocan in OIR models (n = 3) at P15, P18, and P21, rho/VEGF transgenic mice (n = 3) and mice with CNV (n = 5). In these assays above, the eyes from age-matched mice served as control. RT-PCR was used to determine mouse endocan mRNA levels, which were endogenously normalized to cyclophilin A. The protein levels of endocan in these mice models were measured by Western blot assays and β-actin was used for equal protein loading. These data were shown as the mean ± SEM (*P < 0.05; **P < 0.01; ***P < 0.001).
Endocan expression was significantly upregulated in animal models of retinal, subretinal, and choroidal NV.

We examined endocan mRNA and protein expression levels in OIR mice from P13 to P21. RT-PCR analysis revealed that there was a more than 15-fold induction of endocan mRNA expression in the OIR model at P15 and P18 (Fig. 1A), which is in agreement with our microarray results. In addition, immunoblots also showed high expression in retinas of mice with OIR at P15 and P18 (Fig. 1D). While investigating the role of endocan in the subretinal or choroidal NV mice models, we detected that endocan mRNA and protein expression levels were both elevated in CNV (Fig. 1C) and rho/VEGF transgenic mice (Fig. 1B). We therefore concluded that endocan expression was upregulated in our murine ocular NV mouse models and may play an important role in ocular NV development.

**Endocan Staining Increased in OIR and CNV Mice, and Colocalized With Endothelial Cells**

From immunofluorescent staining images of ocular frozen sections of OIR and CNV mice, high expression levels of endocan staining increased in OIR and CNV mice, and colocalized with endothelial cells.
FIGURE 3. Immunofluorescence staining of retinal and choroidal flat-mounts of mice treated with mouse endocan NAb in the OIR, CNV, and rho/VEGF transgenic mouse models. Mice with OIR were randomly divided into several groups and one eye was injected with different concentrations of mouse endocan NAb; the contralateral eye treated with PBS at P12 served as control. (A–E) Retinas were flat-mounted and stained with FITC-lectin at P17 (n = 6 mice/group). (G–H) Choroidal flat-mounts from CNV mice were performed at day 14 (n = 10 mice/group) after laser photocoagulation with ocular treatments at days 0 and 7, as described. (J–K) Rho/VEGF transgenic mice received an intravitreal treatment at P12 and retinas were dissected and stained with FITC-lectin and flat-mounted at P21 (n = 8 mice/group). (F, I, L) Imaging software (Media Cybernetics, Inc.) was used to quantify the area of ocular NV. Statistics were analyzed using 1-way ANOVA with the least-significant difference (LSD) method. Data were shown as mean ± SEM (*P < 0.05; **P < 0.01).
endocan could be observed in the inner layer of the retina of OIR mice (Fig. 2B) and the photocoagulated lesion site with CNV (Fig. 2D). However, lectin-stained vasculature and endocan in the control sections showed faint staining (Figs. 2A, 2C). Merged images did show colocalization of endocan and lectin, which stained for endothelial cells. These findings indicated that endothelial cells might be the main source of endocan secretion participating in retinal and choroidal NV progression.

**Reduction of Retinal, Subretinal, and Choroidal NV by Endocan Neutralization in Ocular NV Animal Models**

Mice with OIR received 1 μL intravitreal injections of endocan NAb in one eye and PBS in the contralateral eye at P12. To determine the lowest effective concentration, dose-effect experiments were designed to treat OIR mice. Analysis of the retinal flat-mounts revealed that endocan blockade significantly suppressed retinal NV at concentrations of 0.5 μg/μL and 1 μg/μL (Figs. 3A–F). We therefore chose 0.5 μg/μL to carry out the subsequent experiments. We also found that the areas of CNV decreased in 0.5 μg/μL endocan NAb neutralized mice (Figs. 3G–I). To further investigate whether endocan NAb treatment was as effective in the VEGF-overexpressing murine model, retinal flat-mounts were examined under fluorescence microscopy, revealing that 0.5 μg/μL endocan NAb significantly suppressed subretinal NV of rho/VEGF mice (Figs. 3J–L). These results demonstrate that endocan may play a supportive role in ocular NV progression related to VEGF.

**Neutralizing Endocan Modulated the Expression of Several Proangiogenic Molecules**

OIR and CNV mice received a 1 μL intravitreal injection of 0.5 μg/μL endocan NAb in one eye and PBS in the contralateral eye at either P12 (OIR) or day 0 (CNV) respectively. RT-PCR was performed to evaluate the mRNA expression of angiogenesis-associated factors in OIR retinas at P15. Angiogenic factors such as VEGF, VEGFR1, VEGFR2, PIGF, and MMP-2 were significantly downregulated (with the exception of MMP-9 and INOS; Fig. 4). Downregulation was further assessed by measuring expression at the protein level during the same period. Intraocular treatment with endocan NAb significantly suppressed the expression of VEGFR1, VEGFR2, PIGF, and MMP-2. These results suggest that endocan may play a supportive role in ocular NV progression related to VEGF.
NAb lowered protein levels in both OIR and CNV models (Fig. 5B) suggesting endocan is involved in the ocular NV process by interacting with angiogenesis-associated molecules.

**Hypoxia and VEGF Induced Endocan Synthesis in HRECs**

We next sought to detect whether endocan could directly modulate endothelial cells in vitro. To mimic the hypoxia-induced OIR model, we cultured HRECs in 1% oxygen. The time curve of mRNA expression showed that endocan was elevated within 24 hours and reached its peak at 6 hours after hypoxia (Fig. 6B). Similar results were obtained from immunoblot (Fig. 6C) and immunofluorescent assays (Fig. 6A). As VEGF was considered to play a central role in ocular NV, we quantified endocan expression after recombinant VEGF stimulation. Notably, endocan expression was induced by VEGF stimulation.

**Endocan Promoted HRECs Tube Formation by Modulating VEGF Signaling**

Compared to controls, incubating HRECs with recombinant endocan could promote endothelial tube formation at 50 ng/mL and 100 ng/mL (Fig. 7A). To further elucidate the underlying mechanism of endocan’s effect on HRECs in vitro, we examined molecules associated with the VEGF pathway (Fig. 7C). We found that VEGF receptor levels were not increased by rhEndocan stimulation. However, phosphorylation levels of both ERK (p-ERK) and p-P38 were increased (p-JNK was not included). These data suggest that endocan may mediate endothelial function by regulating the VEGF signaling pathway via p-ERK and p-P38, the well-established downstream effectors of the VEGF pathway.

**DISCUSSION**

Endocan is known to be essential in the process of pathologic angiogenesis and vascular permeability. Expression levels of endocan are significantly elevated in multiple malignant tumors, and endocan is used as a biomarker for monitoring cancer progression and as a potential therapeutic target. Previous reports established that endocan was implicated in the regulation of inflammation and angiogenesis. However, it is still unclear whether endocan plays a functional role in ocular NV diseases. This study is the first to confirm that endocan expression is significantly elevated at critical time points in established ophthalmic neovascular disease models including OIR, CNV, and rho/VEGF transgenic mice models. We also demonstrated a consistent increase of endocan in HRECs following hypoxia exposure in vitro. Immunofluorescent double-labeling staining showed that endocan was enriched in the surface of the retina of OIR mice and the photoagulated lesion site of CNV mice, colocalizing with isolectin, an endothelial cell marker, suggesting that endothelial cells might be the main source of endocan secretion. Recently, endocan was described to be enriched in “tip cells” which are the motile endothelial cells that mediate sprouting of developing vessels during the process of angiogenesis. Therefore, we hypothesized that endocan might be integral to retinal and subretinal NV progression by regulating retinal endothelial tip cells behavior.

In our prior research, we demonstrated that disruption of the balance between antistatic and angiogenic factors resulted in the formation of pathologic new blood vessels, in which several angiogenic factors were elevated at P15 of the OIR model and at day 3 of CNV mice. Interestingly, these angiogenic molecules, such as VEGFR1, VEGFR2, MMP-2, MMP-9, and PIGF were downregulated after blocking endocan. Consistent with our findings, our new results indicate that the area of retinal, subretinal, and choroidal NV was significantly decreased following the neutralizing effect of an intracocular injection of endocan neutralizing antibody providing additional evidence that endocan plays a proangiogenic role in the ocular NV pathologic process. Further studies are needed to evaluate endocan neutralizing antibody’s potential effects on ocular vascular permeability.

It is well documented that VEGF is an incredibly important stimulator that initiates the sprouting of new blood vessels in retinal and subretinal neovascularization, maintenance of endothelial cell division sustainment and cell survival. PIGF, VEGF, VEGFR1, and VEGFR2 are crucial...
FIGURE 7. Endocan promotes HRECs tube formation by regulating VEGF signaling. (A) Tube formation assays were taken in HRECs in the presence of 50 ng/mL, 100 ng/mL rhEndocan, PBS, or 10 ng/mL rhVEGFA, which served as controls. (B) Data presented represent the mean number of tubes in each treatment group. (C) Western blot to detect protein levels of VEGFR1, VEGFR2, p-P38, and total P38, p-ERK, and total ERK, p-JNK, and total JNK of HRECs lysates after rhEndocan stimulation. Data are expressed as mean ± SEM from three independent experiments. Statistical analysis was performed by 1-way ANOVA with the LSD method (*P < 0.05).
Effects of Endocan on Ocular Angiogenesis

members of the VEGF family. Similar to VEGF, PIGF can directly bind with VEGFR1 and mobilize bone marrow-derived cells and stimulate retinal NV. Clinical investigations have shown that the expressions of PIGF, VEGF, and endocan are upregulated in vitreous fluid from patients with proliferative diabetic retinopathy. Based on our results, inhibition of endocan caused a decrease in VEGF, PIGF and their receptors in the OIR and CNV models, suggesting that the blockade of endocan can modulate angiogenic activities in pathologic NV progression by interacting with VEGF family members. Our results were consistent with previous reports showing that VEGF signaling was reduced in the absence of endocan in the early postnatal mouse retina. Endocan secretion by endothelial cells may act in a paracrine manner in nearby cells during angiogenesis blockage of endocan may interrupt this network. It has been shown that both MMP-2 and MMP-9 are involved in ocular NV progression. MMPs digest extracellular matrix, attributing to early cellular invasiveness through the modulation of MMPs in epithelial tumors migration and metastatic process, indicating that endocan might affect MMP activity during NV development. However, the underlying mechanism remains to be investigated. There is limited evidence to validate that endocan is an upstream or downstream factor of VEGF signaling in ocular NV development. In our experiments, we chose the VEGF overexpressing murine model to investigate the interactions between endocan and VEGF. We observed increased endocan expression levels in VEGF-overexpressing mice and found that inhibition of endocan could suppress VEGF-induced NV in rho/VEGF transgenic mice. In vitro, endocan secretion by HRECs was significantly increased upon recombinant VEGF stimulation. We identified a prominent increase in tube formation of HRECs in the presence of endocan. However, recombinant human endocan alone did not promote HRECs proliferation (data not shown). These results seem reasonable given that new blood vessels formation from preexisting vessels is dependent not only on endothelial proliferation, but also on the appropriate sprouting activity of endothelial cells by interacting with angiogenic factors. Our findings are consistent with prior studies involving bladder cancer research demonstrating that endocan was secreted by microvascularure-derived endothelial cells upon VEGF stimulation and bound VEGF on the cell surface, facilitating its interaction with VEGFR2 and increasing the intensity of VEGF signaling. To uncover the underlying mechanism of endocan mediating HRECs, molecules associated with the VEGF pathway were examined. We demonstrated that endocan stimulation alone did not increase VEGF receptor levels in HRECs. This result is consistent with findings of Rocha et al. that endocan interacts with fibronectin and heparan sulfate proteoglycan 2 instead of directly leading to VEGFR2 phosphorylation. Moreover, we found that endocan modulated the VEGF signaling pathway by regulating downstream effectors p-ERK1 and p-P38. Further studies are needed to determine if the blockade of endocan can provide an additional advantage over current anti-VEGF agents.

In conclusion, our findings in this study indicate that endocan promotes angiogenesis progress in ocular NV by modulating endothelial cell function via upregulation of the VEGF signaling pathway. In addition, the experimental ocular NV in mice and VEGF signaling can be suppressed by endocan blockade. These findings may support targeting endocan as a potential therapy to prevent ocular NV diseases.

Acknowledgments

The authors thank the Shanghai Institute of Burns for place and facility assistance.

Supported by the National Nature Science Foundation of China Grant No. 82470639 and Grant No. 81570853.

Disclosure: T. Su, None; Y. Zhong, None; A.M. Demetriades, None; J. Shen, None; A. Sui, None; Y. Yao, None; Y. Gao, None; Y. Zhu, None; X. Shen, None; B. Xie, None

References

17. Okamoto N, Tobe T, Hackett SF, et al. Transgenic mice with increased expression of vascular endothelial growth factor in


